. 2021 Dec 19;10(24):5970. doi: 10.3390/jcm10245970

Table 5.

Outcome measurements of the volume of included studies for ESWT in BCRL.

Study	Design	No. of Patients (ESWT/Control Group)	Measurement	Volume (Mean ± SD, mL)		Intragroup Difference	Intergroup Difference
Study	Design	No. of Patients (ESWT/Control Group)	Measurement	Baseline	Post-Intervention	Intragroup Difference	Intergroup Difference
Mahran et al., 2015 (Egypt) [38]	RCT	ESWT + CDT: 20	Difference of healthy and affected arm (15 cm above olecranon)	811.9 ± 68.18	285.6 ± 30.06	Yes	Yes
Mahran et al., 2015 (Egypt) [38]	RCT	CDT: 20		797.7 ± 80.33	363.7 ± 24.40	Yes	Yes
El-Shazly et al., 2016 (Egypt) [39]	RCT	ESWT + CDT: 30	Affected arm (N/A)	1219.33 ± 83.42	924.04 ± 94.71	Yes	Yes
El-Shazly et al., 2016 (Egypt) [39]	RCT	CDT: 30	Affected arm (N/A)	1235.40 ± 84.12	1043.85 ± 90.32	Yes	Yes
Lee et al., 2020 (South Korea) [42]	RCT	ESWT + CDT: 15	Difference of healthy and affected arm (axillary level)	840.42 ± 181.33	802.80 ± 149.70	Yes	Yes
Lee et al., 2020 (South Korea) [42]	RCT	CDT: 15	Difference of healthy and affected arm (axillary level)	822.00 ± 144.68	810.00 ± 156.90	No	Yes
Cebicci et al., 2021 (Turkey) [43]	RCT	ESWT: 10	Difference of healthy and affected arm (axillary level)	932.0 ± 341.9	795.0 ± 360.9	Yes	No
Cebicci et al., 2021 (Turkey) [43]	RCT	CDT: 10	Difference of healthy and affected arm (axillary level)	800.0 ± 402.7	675.0 ± 345.8	Yes	No
Cebicci et al., 2016 (Turkey) [27]	Prospective pilot study	ESWT: 11	Difference of healthy and affected arm (axillary level)	870.4 ± 115.1	736.36 ± N/A	Yes	N/A
Joos et al., 2020 (Belgium) [44]	Prospective pilot study	ESWT + CDT: 10	Affected arm (N/A)	3086.4 ± 539.47	2909.1 ± 471.60	No	N/A

Abbreviations: ESWT: Extracorporeal shock wave therapy; BCRL: Breast cancer-related lymphedema; No.: Number; SD: Standard deviation; mL: milliliter; RCT: Randomized controlled trial; CDT: Complex decongestive therapy; N/A: Not available.